Clinical Trial Update: A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status [Phase 1]

View source ↗

Summary

Phase I study of AC220 (trastuz? actually AC220 is quizartinib, a FLT3 inhibitor) in relapsed/refractory AML regardless of FLT3 status; completed with posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AC220 (quizartinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Acute Myeloid Leukemia, Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2020-04-24